Osteopathic Association: Kratom An Opioid Alternative, Ban Would Stifle Science

December 5, 2016December 12, 2018Big Pharma

Total23
19
4
0
Like

Share via

The Journal of the American Osteopathic Association has just asserted that a delayed U.S. Drug Enforcement Administration ban on the kratom plant would stifle scientific understanding of the herb’s active chemical components and documented pharmacologic properties – if it goes through.

The special report cited the pharmacologically active compounds in kratom, including mitragynine, 7-hydroxymitragynine, paynantheine, speciogynine and 20 other substances as a reason to preserve rights to study it. Previously, only a couple of components were relatively known and, as it turns out, the government appears to have a keen interest in patents on them.

Additionally, the report stressed the vast amount of anecdotes and current research that demonstrates the herb to be a safe and non-addictive alternative to opioids which have proven to be disastrous and even deadly. There are now more people addicted to opioids than nicotine.

Widget not in any sidebars

Study author Walter Prozialeck, chairman of the Department of Pharmacology at Midwestern University Chicago College of Osteopathic Medicine, said:

There’s no question kratom compounds have complex and potential useful pharmacologic activities and they produce chemically different actions from opioids.

Kratom doesn’t produce an intense euphoria and, even at very high doses, it doesn’t depress respiration, which could make it safer for users

Prozialeck points out that even breast cancer treatments like tamoxifen were developed from plant research. Again, if we are to believe that kratom is an “emerging health threat” as the CDC would have us believe – then why does the government own patents for the component? It sounds like the government may be hoarding kratom for the drug companies; whereas, kratom could benefit people as a consumer product and in the medical field.

Science Daily reports:

Kratom (Mitragyna speciosa) is indigenous to Southeast Asia, where the plant was used for centuries to relieve fatigue, pain, cough and diarrhea and aid in opioid withdrawal. Currently sold in the United States as an herbal supplement, kratom drew DEA scrutiny after poison control centers noted 660 reports of adverse reactions to kratom products between January 2010 and December 2015.

Anita Gupta, DO, PharmD and special advisor to the FDA, responds to those claims by saying:

While the DEA and physicians have valid safety concerns, it is not at all clear that kratom is the culprit behind the adverse effects.

In fact, many of those victims were found to have pharmaceuticals like antidepressants in their bodies, yet those have not come under the recent heat lamp.